Z-Lys(Boc)-Lys(Boc)-OMe | 23556-66-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Z-Lys(Boc)-Lys(Boc)-OMe
• 英文别名: methyl (2S)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[[(2S)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(phenylmethoxycarbonylamino)hexanoyl]amino]hexanoate
• CAS: 23556-66-3
• 化学式: C₃₁H₅₀N₄O₉
• 分子量: 622.759
• InChiKey: BNBIRFAHFOIAMH-ZEQRLZLVSA-N

物化性质

• 沸点：
  784.1±60.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  44
• 可旋转键数：
  22
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  170
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  Z-Lys(Boc)-Lys(Boc)-OMe 在 lithium hydroxide monohydrate 、 palladium 10% on activated carbon 、 氢气 、 1-羟基苯并三唑 作用下， 以 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 80.99h， 生成 N-alpha-carbobenzoxy-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysyl-N-epsUon-t-butyloxycarbonyl-L-lysyl-N-epsilon-t-butyloxycarbonyl-L-lysyl-A/-epsilon-t-butyloxycarbonyl-L-lysine
  参考文献：
  名称：

  Chloride-Assisted Peptide Macrocyclization

  摘要：

  The role of the Cl- anion as a templating agent for the synthesis of cyclopeptides was assessed through the preparation of three new homocyclolysines and other six cyclic peptides by head-to-tail lactamization. Isolated yields of products obtained by chloride-templating approach were considerably higher than those gained by a cation-promoted procedure, whereby, in some cases, only the anion-assisted synthesis yielded the desired cyclopeptides.

  DOI：

  10.1021/acs.orglett.0c00036
• 作为产物：
  描述：

  Nε-Boc-Nα-Cbz-L-赖氨酸 、 N-Boc-L-赖氨酸甲酯盐酸盐 在 2,6-二甲基吡啶 、 (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate 作用下， 以 水 为溶剂， 反应 1.0h， 以92%的产率得到Z-Lys(Boc)-Lys(Boc)-OMe
  参考文献：
  名称：

  MC-1。一种“设计”表面活性剂，专为室温下水中的肽合成而设计

  摘要：

  胶束水催化作用先前已被证明是绿色肽合成的一项可行技术。然而，响应于在肽结构中使用选定氨基酸的局限性，在环境上令人讨厌的偶极非质子溶剂DMSO的普遍使用的启发下，已经设计了一种新的表面活性剂。新的两亲物MC-1将高极性砜组分引入表面活性剂的非极性区域，从而引入其衍生的纳米胶束的内芯。这不仅导致解决了溶解性问题，而且导致了高收率，易于处理反应混合物以及消除了助溶剂。革兰氏反应也在本文中描述。

  DOI：

  10.1039/c9gc01050e

文献信息

• MC-1. A “designer” surfactant engineered for peptide synthesis in water at room temperature
  作者：Margery Cortes-Clerget、Summer E. Spink、Gregory P. Gallagher、Laurent Chaisemartin、Edith Filaire、Jean-Yves Berthon、Bruce H. Lipshutz

  DOI：10.1039/c9gc01050e

  日期：——

  Aqueous micellar catalysis has previously been shown to be an enabling technology for green peptide synthesis. Nonetheless, in response to limitations associated with use of selected amino acids in peptide constructions, a new surfactant has been designed, inspired by the commonplace use of the environmentally egregious dipolar aprotic solvent DMSO. A new amphiphile, MC-1, introduces a highly polar

  胶束水催化作用先前已被证明是绿色肽合成的一项可行技术。然而，响应于在肽结构中使用选定氨基酸的局限性，在环境上令人讨厌的偶极非质子溶剂DMSO的普遍使用的启发下，已经设计了一种新的表面活性剂。新的两亲物MC-1将高极性砜组分引入表面活性剂的非极性区域，从而引入其衍生的纳米胶束的内芯。这不仅导致解决了溶解性问题，而且导致了高收率，易于处理反应混合物以及消除了助溶剂。革兰氏反应也在本文中描述。
• LIGAND-TARGETED MOLECULES AND METHODS THEREOF
  申请人：INVICTUS ONCOLOGY PVT.LTD.

  公开号：US20150045428A1

  公开（公告）日：2015-02-12

  The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, which in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O→Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention.

  本发明涉及配体靶向分子和配体药物结合物（LDCs），其中配体连接到功能基团，功能基团连接到连接剂，连接剂又与药物结合。本发明的LDCs还包括铂配位络合物，其中铂通过单羧酸盐和O→Pt配位键与连接剂连接。本发明还涉及制备这些配体药物结合物的方法。本发明还涉及使用本发明的配体药物结合物治疗肿瘤的方法。
• Polypeptides with ACTH-like activities
  申请人：Shionogi & Co., Ltd.

  公开号：US04018753A1

  公开（公告）日：1977-04-19

  A polypeptide of the formula: X.sub.1 -Tyr-Ser-X.sub.2 -X.sub.3 -His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-(Lys).sub.n -Y wherein X.sub.1 is .alpha.-aminoisobutyric acid, .beta.-alanine, L-serine, glycine, D-serine, D-alanine, .gamma.-aminobutyric acid or sarcosine residue; X.sub.2 is L-methionine, L-norleucine, L-isoleucine or L-norvaline residue; X.sub.3 is L-glutamic acid or L-glutamine residue; n is an integer of 1-4 and Y is a group of ##STR1## which is linked to the carbonyl group of the C-terminal lysine residue, wherein R.sub.1 and R.sub.2 are each hydrogen or the same or different lower alkyl having 1-5 carbon atoms, and R.sub.1 and R.sub.2, when taken together with or without another hetero atom, form a substituted or unsubstituted nitrogen containing heterocyclic ring, with the proviso that a peptide when X.sub.1 is a .alpha.-aminoisobutyric acid or D-serine, R.sub.1 and R.sub.2 are each hydrogen and n is 4 is excluded; non-toxic acid addition salts thereof and complexes thereof; being useful as a medicament owing to their strong adrenal-stimulating activity with protracted action and little side effects. They can be prepared by condensing the amino acids together one by one or by condensing the small peptide fragments together in a per se conventional manner.

  一种多肽的化学式：X.sub.1-Tyr-Ser-X.sub.2-X.sub.3-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-(Lys).sub.n-Y，其中X.sub.1是α-氨基异丁酸、β-丙氨酸、L-丝氨酸、甘氨酸、D-丝氨酸、D-丙氨酸、γ-氨基丁酸或肌氨酸残基；X.sub.2是L-蛋氨酸、L-去亮氨酸、L-异亮氨酸或L-去缬氨酸残基；X.sub.3是L-谷氨酸或L-谷氨酰胺残基；n是1-4的整数，Y是一个与C端赖氨酸残基的羰基基团相连的##STR1##，其中R.sub.1和R.sub.2分别是氢或具有1-5个碳原子的相同或不同的低级烷基，当R.sub.1和R.sub.2与其他杂原子一起或不带其他杂原子形成取代或未取代的含氮杂环时，多肽在X.sub.1为α-氨基异丁酸或D-丝氨酸，R.sub.1和R.sub.2均为氢且n为4时被排除；其非毒性酸盐和配合物；由于它们具有持久作用和少副作用的强肾上腺刺激活性，因此可用作药物。它们可以通过逐个缩合氨基酸或按照常规方法缩合小肽片段来制备。
• Studies on Polypeptides. XXVIII. Elimination of the Methionine Residue as an Essential Functional Unit for <i>in Vivo</i> Adrenocorticotropic Activity^1-4
  作者：Klaus. Hofmann、Joachim. Rosenthaler、Robert D. Wells、Haruaki. Yajima

  DOI：10.1021/ja01076a052

  日期：1964.11
• Synthese von lipophil substituierten ACTH-Peptiden
  作者：M. Brugger

  DOI：10.1002/hlca.19710540505

  日期：——

  AbstractWith a view to rendering ACTH peptides absorbable by the oral route, a series of such peptides with increased lipophilic character was built up. This paper describes the synthesis of eleven derivatives of the ACTH peptide [D‐Ser1, Lys17,18]‐β‐corticotrophin‐(1–19)‐nonadeca‐peptide, containing lipophilic alkyl substituents of different kinds and sizes, bound to the carboxyl of terminal proline either by ester or amide linkage.The unsubstituted peptide [D‐Ser1, Lys17,18]‐β‐corticotrophin‐(1–19)‐nonadecapeptide, and its C‐terminal amide were also synthesized.